Key facts
- It has raised $260.6M; the latest was PE Growth/Expansion ($110.3M) in Apr 2026.
- Notable investors include International Finance (Washington D.C.), European Investment Bank.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Biovac (Africa)
- ·The full record, as it builds
Funding rounds
No funding rounds for Biovac (Africa) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Biovac (Africa)
Operator of a bio-pharmaceutical company intended to manufacture vaccines for national health management and security. The company makes vaccines for diseases like tuberculosis, measles, pneumonia, tetanus, and hepatitis, enabling patients to avail of advanced treatment.
- Sector
- Healthcare
- HQ
- Cape Town, South Africa
- Founded
- 2003
- Employees
- 320
- Website
- biovac.co.za/
- Ownership
- Privately Held (backing)
Biovac (Africa) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biovac (Africa) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biovac (Africa) in its N-PORT filings yet. We sweep new filings monthly.